Witte, Michael M.Foster, Norman L.Fleisher, Adam S.Williams, Monique M.Quaid, KimberlyWasserman, MichaelHunt, GailRoberts, J. ScottRabinovici, Gil D.Levenson, James L.Hake, Ann MarieHunter, Craig A.Van Campen, Luann E.Pontecorvo, Michael J.Hochstetler, Helen M.Tabas, Linda B.Trzepacz, Paula T.2016-03-112016-03-112015-09Witte, M. M., Foster, N. L., Fleisher, A. S., Williams, M. M., Quaid, K., Wasserman, M., ... & Hake, A. M. (2015). Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 1(3), 358-367.https://hdl.handle.net/1805/8813Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesAlzheimer's diseasemild cognitive impairmentbioethics in neurologyArticle